| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
94 |
| Employees |
24 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-4 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Nymox Pharmaceutical Corporation is a biopharmaceutical company primarily focused on developing and commercializing pharmaceutical products for the diagnosis and treatment of various urological and neurodegenerative disorders. The company utilizes its proprietary technologies and expertise to develop innovative solutions that address unmet medical needs.
Nymox is known for its lead product, NX-1207, which is in advanced development as a potential treatment for benign prostatic hyperplasia (BPH), a common condition in aging men characterized by an enlarged prostate gland. The company's technology platform involves using genetically engineered proteins to target and shrink the enlarged prostate gland, providing relief from BPH symptoms without the need for surgery or invasive procedures.
In addition to BPH, Nymox is also involved in research and development efforts to discover potential treatments for Alzheimer's disease and other neurodegenerative disorders. The company utilizes its scientific expertise and collaborations to identify novel therapeutic targets and develop effective drug candidates.
Nymox Pharmaceutical Corporation is dedicated to improving patients' quality of life by developing safe and effective treatments for urological and neurodegenerative disorders. The company's commitment to innovation, scientific excellence, and patient-centric approach sets it apart in the pharmaceutical industry.
Company Address: Bay & Deveaux Streets Nassau 0
Company Phone Number: 936-9669 Stock Exchange / Ticker: NYMX
|
%
4.63%